Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug development in anaesthesia: industrial perspective.

Gavin J Kilpatrick1, Gary S Tilbrook

  • 1CeNeS Limited, Compass House, Cambridge, UK. gavin.kilpatrick@cenes.com

Current Opinion in Anaesthesiology
|July 11, 2006
PubMed
Summary

New anesthesia drugs are in development, including propofol prodrugs and novel sedatives. Limited drug discovery activity may stem from industry perceptions, highlighting a need for better communication of anesthesiologist requirements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent.

Frontiers in pharmacology·2021
Same author

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures.

Frontiers in immunology·2021
Same author

A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.

Anesthesia and analgesia·2012
Same author

A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.

Anesthesia and analgesia·2011
Same author

CNS 7056: a novel ultra-short-acting Benzodiazepine.

Anesthesiology·2007
Same author

Morphine-6-glucuronide: actions and mechanisms.

Medicinal research reviews·2005

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Drug Development

Background:

  • The field of anesthesia is continuously evolving with new therapeutic agents.
  • Understanding the mechanisms of action for existing anesthetics is crucial for developing novel drugs.
  • Despite advances, there remains a need for improved sedative, hypnotic, and analgesic agents.

Purpose of the Study:

  • To review and summarize novel drugs currently in development within the field of anesthesia.
  • To identify emerging trends and potential therapeutic targets in anesthetic drug discovery.
  • To assess the current landscape of drug development for sedatives, hypnotics, and neuromuscular blockers.

Main Methods:

  • Literature review of recent publications and clinical trial data.

Related Experiment Videos

  • Analysis of drug development pipelines for anesthetic agents.
  • Identification of novel drug candidates and their proposed mechanisms of action.

    • Main Results:

    • Several novel drug candidates are in development, including propofol prodrugs (e.g., Aquavan) and new 'soft-drug' sedatives/hypnotics (e.g., CNS-7259X, TD-4756).
    • Sugammadex represents a novel approach for reversing steroidal neuromuscular blockers.
    • Significant activity is noted in novel analgesics, but less so for sedatives, hypnotics, and neuromuscular blockers.
    • New targets, such as the beta3-subunit of GABA-A receptors, show promise for developing agents with improved safety profiles.

    Conclusions:

    • The perception of low need for new anesthesia drugs in the industry may be hindering development.
    • Anesthesiologists must effectively communicate their unmet needs to stimulate further drug discovery.
    • Targeting specific receptor subunits, like those in GABA-A, offers potential for safer and more effective anesthetic agents.